425 related articles for article (PubMed ID: 34522598)
21. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes.
Koushik K; Dhanda DS; Cheruvu NP; Kompella UB
Pharm Res; 2004 Jul; 21(7):1119-26. PubMed ID: 15290850
[TBL] [Abstract][Full Text] [Related]
23. Deposition of inhaled particles in the lungs.
Fernández Tena A; Casan Clarà P
Arch Bronconeumol; 2012 Jul; 48(7):240-6. PubMed ID: 22464044
[TBL] [Abstract][Full Text] [Related]
24. Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation.
Schneider CS; Xu Q; Boylan NJ; Chisholm J; Tang BC; Schuster BS; Henning A; Ensign LM; Lee E; Adstamongkonkul P; Simons BW; Wang SS; Gong X; Yu T; Boyle MP; Suk JS; Hanes J
Sci Adv; 2017 Apr; 3(4):e1601556. PubMed ID: 28435870
[TBL] [Abstract][Full Text] [Related]
25. An innovative corticosteroid/long-acting β
Usmani O; Roche N; Marshall J; Danagher H; Price D
Expert Opin Drug Deliv; 2019 Dec; 16(12):1367-1380. PubMed ID: 31752560
[No Abstract] [Full Text] [Related]
26. Application of inhaled drugs from the pharmacists point of view.
Masaryková L; Polaščíková P
Ceska Slov Farm; 2020; 69(4):172-184. PubMed ID: 33291934
[TBL] [Abstract][Full Text] [Related]
27. Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects.
Xu Y; Thakur A; Zhang Y; Foged C
Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33525500
[TBL] [Abstract][Full Text] [Related]
28. Advances in asthma and COPD management: delivering CFC-free inhaled therapy using Modulite technology.
Acerbi D; Brambilla G; Kottakis I
Pulm Pharmacol Ther; 2007; 20(3):290-303. PubMed ID: 16890465
[TBL] [Abstract][Full Text] [Related]
29. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
[TBL] [Abstract][Full Text] [Related]
30. Inhaled lipid nanocarriers for pulmonary delivery of glucocorticoids: Previous strategies, recent advances and key factors description.
Altube MJ; Perez N; Romero EL; Morilla MJ; Higa LH; Perez AP
Int J Pharm; 2023 Jul; 642():123146. PubMed ID: 37330156
[TBL] [Abstract][Full Text] [Related]
31. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
Wang YB; Watts AB; Peters JI; Williams RO
Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
[TBL] [Abstract][Full Text] [Related]
32. Inhaled drug delivery in the hands of the patient.
Lavorini F
J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):414-8. PubMed ID: 25238005
[TBL] [Abstract][Full Text] [Related]
33. A Pathway From Porous Particle Technology Toward Tailoring Aerogels for Pulmonary Drug Administration.
Duong T; López-Iglesias C; Szewczyk PK; Stachewicz U; Barros J; Alvarez-Lorenzo C; Alnaief M; García-González CA
Front Bioeng Biotechnol; 2021; 9():671381. PubMed ID: 34017828
[TBL] [Abstract][Full Text] [Related]
34. Oral delivery of proteins and peptides: Challenges, status quo and future perspectives.
Zhu Q; Chen Z; Paul PK; Lu Y; Wu W; Qi J
Acta Pharm Sin B; 2021 Aug; 11(8):2416-2448. PubMed ID: 34522593
[TBL] [Abstract][Full Text] [Related]
35. Inhalable PLGA microspheres: Tunable lung retention and systemic exposure via polyethylene glycol modification.
Li J; Zheng H; Xu EY; Moehwald M; Chen L; Zhang X; Mao S
Acta Biomater; 2021 Mar; 123():325-334. PubMed ID: 33454386
[TBL] [Abstract][Full Text] [Related]
36. Treatment of bleomycin-induced pulmonary fibrosis by inhaled tacrolimus-loaded chitosan-coated poly(lactic-co-glycolic acid) nanoparticles.
Lee C; Seo J; Hwang HS; Thao LQ; Lee S; Lee ES; Lee EH; Choi HG; Youn YS
Biomed Pharmacother; 2016 Mar; 78():226-233. PubMed ID: 26898446
[TBL] [Abstract][Full Text] [Related]
37. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler.
Sorino C; Negri S; Spanevello A; Visca D; Scichilone N
Eur J Intern Med; 2020 May; 75():15-18. PubMed ID: 32113944
[TBL] [Abstract][Full Text] [Related]
38. Formulation strategy and use of excipients in pulmonary drug delivery.
Pilcer G; Amighi K
Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
[TBL] [Abstract][Full Text] [Related]
39. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
[TBL] [Abstract][Full Text] [Related]
40. A Systematic Safety Evaluation of Nanoporous Mannitol Material as a Dry-Powder Inhalation Carrier System.
Zhang X; Yue X; Cui Y; Zhao Z; Huang Y; Cai S; Wang G; Wang W; Hugh S; Pan X; Wu C; Tan W
J Pharm Sci; 2020 May; 109(5):1692-1702. PubMed ID: 31987851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
